Evaluation of temporal muscle thickness in subjects with acromegaly: a follow-up study
Por:
Navas-Moreno, V, Araujo-Castro, M, Tapia-Sanchiz, MS, Sebastián-Valles, F, Sampedro-Núñez, MA, de la Blanca, NS, Martínez-Hernández, R, Rodríguez-Laval, V, Blanco, C, Biagetti, B, Puig-Domingo, M and Marazuela, M
Publicada:
1 ene 2026
Resumen:
Background: Growth hormone and insulin-like growth factor 1 (IGF-1) have recently been linked to temporal muscle thickness (TMT) in acromegaly; however, the relationship between treatment response and TMT remains unclear. Objectives: To evaluate whether TMT correlates with treatment response and may serve as a surrogate marker of disease control in patients with acromegaly. Design: Retrospective longitudinal two-center study. Methods: Patients with acromegaly and non-functioning pituitary adenomas (NFPA) were included. TMT was measured on magnetic resonance imaging scans obtained before treatment initiation and after a 3-year follow-up. Baseline TMT was compared between groups. In patients with acromegaly, TMT was correlated with IGF-1 levels at diagnosis and over time, as well as with treatment response. Mixed-effects regression models adjusted for covariates were used to assess associations. Results: Imaging studies from 58 subjects were analyzed (40 with acromegaly, 18 with NFPA). Pre-treatment TMT was significantly greater in patients with acromegaly compared with NFPA (mean 10.1 mm (9.3-10.7) vs 8.1 mm (8.0-9.2), p = 0.003). Higher baseline TMT was associated with higher IGF-1 levels at diagnosis (p < 0.01). Following treatment, mean TMT decreased from 9.6 mm at baseline to 8.8 mm at 36 months (p = 0.001). In covariate-adjusted mixed-effects models, higher pre-treatment TMT was independently associated with increased IGF-1 levels at diagnosis and longitudinally (beta = 19.59 ng/mL, p = 0.022). Conclusion: TMT correlates with biochemical disease activity and decreases after treatment, suggesting it may be a useful imaging marker of clinical activity and prognosis in acromegaly.
Filiaciones:
Navas-Moreno, V:
Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain
Araujo-Castro, M:
Hosp Univ Ramon & Cajal, Dept Endocrinol & Nutr, Madrid, Spain
Inst Invest Biomed Ramon & Cajal, Madrid, Spain
Tapia-Sanchiz, MS:
Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain
Sebastián-Valles, F:
Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain
Sampedro-Núñez, MA:
Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain
de la Blanca, NS:
Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER G, Madrid, Spain
Martínez-Hernández, R:
Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER G, Madrid, Spain
Rodríguez-Laval, V:
Hosp Univ Princesa, Dept Radiol, Madrid, Spain
Blanco, C:
Principe Asturias Univ Hosp, Dept Endocrinol & Nutr, Madrid, Spain
Biagetti, B:
Hosp Univ Vall Hebron, Endocrinol & Nutr Dept, CIBERER ISCIII U747, ENDO ERN, Barcelona, Spain
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias i Pujol, Endocrinol & Nutr Dept, CIBERER ISCIII U747, Badalona, Spain
Marazuela, M:
Univ Autonoma Madrid, Hosp Univ Princesa, Dept Endocrinol & Nutr, Inst Invest Sanitaria Princesa, Madrid, Spain
gold
|